Meeting the Challenges of Drug Discovery
Organizer(s): Stephen W. Fesik and Michael D. VarneyDate: January 15 - 20, 2005
Location: Fairmont Hotel Vancouver, Vancouver, BC, Canada
The drug discovery process is difficult, challenging, costly, and often leads to failure. Nevertheless, it is critical that we continue to discover new drugs to meet the many unmet medical needs. To reduce the costs and improve the success of drug discovery and development, new technologies and strategies have been developed. To aid in the target identification and validation steps of the drug discovery process, RNAi technology for gene knockdown is playing an important role along with large-scale gene knockouts in animals. Novel screening approaches, high-throughput synthesis, iterative structure-based design, and in vitro toxicity assays are aiding lead identification and optimization. In addition, approaches are being developed for identifying and utilizing biomarkers in clinical trials to improve the success of drug approval. Advances have also been made in the discovery of biomolecules for the treatment of disease. In this Keystone Symposium, approaches for streamlining and improving drug discovery and development will be discussed that include enabling technologies to aid in target identification/validation and lead identification/optimization, strategies for discovering and applying DNA, RNA, and protein biomarkers in pre-clinical studies and clinical trials, and the use of biologicals to treat disease. In addition, success stories on new drug candidates will be presented.
Discounted Abstract Deadline: September 20 2004
Discounted Registration Deadline: November 15 2004
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
Agouron Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
AVEO Pharmaceuticals, Inc.
Bristol-Myers Squibb Company
Iconix Biosciences, Inc.
Isis Pharmaceuticals, Inc.
Lexicon Pharmaceuticals Inc.
Merck Research Laboratories
Novartis Institutes for BioMedical Research
Ozgene Pty Ltd
Vertex Pharmaceuticals Incorporated